



Alzinova announces change of Certified Adviser and Liquidity Provider

Alzinova AB (Ticker: ALZ) hereby announces that the company changes Certified Adviser from Redeye AB ("Redeye") to Mangold Fondkommission AB ("Mangold"). Furthermore, the company announces that the liquidity provider agreement with Carnegie Investment Bank AB ("Carnegie") has been terminated and will be replaced with Mangold as liquidity provider.

Alzinova has entered into an agreement with Mangold regarding the service as Certified Adviser. Mangold will be appointed Certified Adviser (CA) on July 1, 2024. Until then, Redeye AB will continue to act as Certified Adviser for the Company.

Alzinova has also terminated the agreement with Carnegie on the assignment as liquidity provider. The last day of liquidity support trading by Carnegie is June 30, 2024. Alzinova has entered into a new liquidity provider agreement with Mangold, which will act as liquidity provider for Alzinova's shares as of July 1, 2024.

The liquidity provision assignment is offered in accordance with the rules of Nasdaq First North Growth Market and means that the liquidity provider continuously quotes a buy and sell volume corresponding to at least SEK 15,000, with a maximum spread of 4% between the bid and ask price. The purpose of the agreement is to promote liquidity in the trading of the share. The agreement and the trading of the liquidity provider will start from July 1, 2024.

For more information, please contact:

Kristina Torfgård, CEO
Tel. +46 708 46 79 75
E-mail: kristina.torfgard@alzinova.com

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.

About Alzinova

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A β CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: www.alzinova.com



Attachments

Alzinova announces change of Certified Adviser and Liquidity Provider